SCHEMBL3014145

SCHEMBL3014145

O=S(=O)(c1ccc(F)cc1Cl)C1CCN(c2nc(-c3cccc(Br)c3)cs2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.51
SMN1; SMN2 Q16637 9/20 0.46
RAB9A P51151 6/20 0.46
MAPT P10636 2/20 0.46
USP2 O75604 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
L3MBTL1 Q9Y468 4/20 0.43
NPC1 O15118 5/20 0.43
MMP2 P08253 1/20 0.42
MMP8 P22894 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011005 0.93 SMN1; SMN2 (0.49) CTSSSMN1; SMN2RAB9AMAPTALDH1A1
SCHEMBL3000176 0.91 MAPT (0.45) CTSSSMN1; SMN2RAB9AMAPTUSP2
SCHEMBL3016314 0.91 SMN1; SMN2 (0.52) CTSSSMN1; SMN2RAB9AMAPTALDH1A1
SCHEMBL3013324 0.90 CTSS (0.52) CTSSSMN1; SMN2RAB9AMAPTUSP2
SCHEMBL3018127 0.89 CTSS (0.51) CTSSSMN1; SMN2RAB9AMAPTUSP2
SCHEMBL3014477 0.89 SMN1; SMN2 (0.52) CTSSSMN1; SMN2RAB9AMAPTALDH1A1
SCHEMBL3008593 0.88 MAPT (0.47) SMN1; SMN2RAB9AMAPTUSP2RECQL
SCHEMBL3018181 0.87 AR (0.53) CTSSSMN1; SMN2RAB9AMAPTUSP2
SCHEMBL3019881 0.87 MAPT (0.63) CTSSSMN1; SMN2MAPTUSP2RECQL
SCHEMBL3011275 0.87 CTSS (0.51) CTSSSMN1; SMN2RAB9AMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.